Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine combination capable of reducing myocardial infarction area and use thereof

一种心肌梗死、组合物的技术，应用在含其的药物制剂领域，能够解决血压波动、缩小心肌梗死没有达到、不能耐受等问题

Active Publication Date: 2009-01-07
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although the above-mentioned drugs mainly for improving hemodynamics are commonly used clinically to treat myocardial infarction and angina pectoris, there are still many problems. The therapeutic effect of these drugs and treatments on reducing the size of myocardial infarction has not reached the expected level. Human medication is prone to side effects such as blood pressure fluctuations, bradycardia, and aggravation of heart failure, which cannot be tolerated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 To observe the protective effects of trimetazidine, levocarnitine and trimetazidine+levocarnitine in different dosage ratios on acute myocardial infarction in rats.

[0044] Trimetazidine and levocarnitine were used to calculate the equivalent doses for rats based on the human doses recommended by the manufacturer. Four dose groups were set up for each drug, and there were 5 groups in total as solvent-added controls. They are:

[0045] Trimetazidine: solvent control group, trimetazidine drugs 1, 3, 6, 9 mg / kg.

[0046] Levocarnitine: solvent control group, levocarnitine 100, 300, 600, 900mg / kg.

[0047] The dosage of trimetazidine+levocarnitine, according to the efficacy of trimetazidine and levocarnitine, after removing the highest dose of the two groups, the dosage of trimetazidine+levocarnitine ( mg / kg) was set to 3+100, 3+300, 3+600, 1+300, 6+300, plus solvent control, a total of 6 groups.

[0048] Male SD rats with a body weight of 200±20 grams were se...

Embodiment 2

[0061] Example 2 To observe the protective effect of trimetazidine + levocarnitine in different dosage ratios on acute myocardial infarction in rats.

[0062] The dosage of trimetazidine+levocarnitine, according to the efficacy of trimetazidine and levocarnitine, after removing the highest dose of the two groups, the dosage of trimetazidine+levocarnitine ( mg / kg) are set as in Table 4.

[0063] Male SD rats with a body weight of 200±20 grams were selected. Animals were weighed, and a single dose was administered intraperitoneally, with a dose volume of 5 ml / kg. Immediately anesthetized with ether, fixed on the mouse table in supine position, disinfected the skin of the left chest with 75% alcohol, opened the chest along the 3rd-4th intercostal space along the left sternal border, cut the pericardium, exposed the heart, and found it between the conus pulmonary artery and the left atrial appendage. Out of the anterior descending coronary artery, use a round non-invasive suture...

Embodiment 3

[0066] Example 3 Combination pharmaceutical preparations of levocarnitine: trimetazidine in different dosage ratios.

[0067] The combined drug containing levocarnitine and trimetazidine of the present invention can prepare various combined drug preparations containing different levocarnitine and trimetazidine dosage ratios according to the following data:

[0068] Levocarnitine 10mg-600mg / kg / day; trimetazidine 0.01mg-3mg / kg / day

[0069] Determine the ratio range from 30g:1mg to 0.5g:200mg

[0070] Levocarnitine: Trimetazidine Levocarnitine (heavy): Trimetazidine (heavy)

[0071] 1:0.000016 1000g:16mg

[0072] 1:0.00004 1000g:40mg

[0073] 1:0.00005 1000g:50mg

[0074] 1:0.0001 1000g:100mg

[0075] 1:0.0005 1000g:500mg

[0076] 1:0.001 1000g:1g

[0077] 1:0.002 1000g:2g

[0078] 1:0.003 1000g:3g

[0079] 1:0.004 1000g:4g

[0080] 1:0.005 1000g:5g

[0081] 1:0.006 1000g:6g

[0082] 1:0.007 1000g:7g

[0083] 1:0.008 1000g:8g

[0084] 1:0.009 1000g:9g

[0085] 1:0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for reducing myocardial infarction area, and a pharmaceutical preparation containing the same and an application thereof. The pharmaceutical composition comprises levocarnitine or a derivative thereof and a drug for improving hemodynamics. The dosages of levocarnitine or the derivative thereof and the drug for improving hemodynamics are dosages capable of effectively reducing myocardial infarction area.

Description

technical field [0001] The invention relates to the field of medicaments, in particular to a pharmaceutical composition for reducing the size of myocardial infarction, its application and a pharmaceutical preparation containing the same. technical background [0002] Myocardial infarction (AMI) is a combination of atheromatous plaque rupture and hemorrhage and intravascular thrombosis on the basis of coronary atherosclerosis, resulting in rapid and persistent occlusion of the lumen, interruption of blood flow, and partial myocardial infarction due to severe and persistent ischemia. And local necrosis occurs. According to the clinical process and electrocardiographic manifestations, it can be divided into three stages: acute, subacute and chronic, but the clinical symptoms mainly appear in the acute stage, and the mortality rate is the highest in the first week of the acute stage. Acute myocardial infarction is a common critical illness that threatens human life, and it is a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/205A61K31/495A61K9/08A61K9/02A61K9/06A61K9/10A61K9/107A61K9/14A61K45/06A61P9/02A61P9/04A61P9/10A61K31/21A61K31/403A61K31/4422
CPCA61K9/2054A61K31/495A61K9/02A61K9/2018A61K9/0095A61K9/2027A61K9/1623A61K9/0056A61K9/0019A61K9/1635A61P9/02A61P9/04A61P9/10
Inventor 顾书华梅长林苏定冯杜娟樊榕
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com